Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis.

MLA

Wakabayashi, Naoto, et al. “Safety and Efficacy of Multiple-Dose versus Single-Dose MIBG Therapy in Patients with Refractory Pheochromocytoma and Paraganglioma: A Single-Center Retrospective Analysis.” Annals of Nuclear Medicine, vol. 38, no. 7, July 2024, pp. 553–62. EBSCOhost, https://doi.org/10.1007/s12149-024-01928-2.

APA

Wakabayashi, N., Watanabe, S., Abe, T., Takenaka, J., Hirata, K., Kimura, R., Sakamoto, K., Shinohara, N., & Kudo, K. (2024). Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis. Annals of Nuclear Medicine, 38(7), 553–562. https://doi.org/10.1007/s12149-024-01928-2

Chicago

Wakabayashi, Naoto, Shiro Watanabe, Takashige Abe, Junki Takenaka, Kenji Hirata, Rina Kimura, Keita Sakamoto, Nobuo Shinohara, and Kohsuke Kudo. 2024. “Safety and Efficacy of Multiple-Dose versus Single-Dose MIBG Therapy in Patients with Refractory Pheochromocytoma and Paraganglioma: A Single-Center Retrospective Analysis.” Annals of Nuclear Medicine 38 (7): 553–62. doi:10.1007/s12149-024-01928-2.